At the time of writing, Vertex Pharmaceuticals, Inc [VRTX] stock is trading at $410.28, up 1.83%. An important factor to consider is whether the stock is rising or falling in short-term value. The VRTX shares have gain 4.76% over the last week, with a monthly amount glided 3.80%, and seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
Vertex Pharmaceuticals, Inc [NASDAQ: VRTX] stock has seen the most recent analyst activity on September 25, 2025, when Leerink Partners upgraded its rating to a Outperform but kept the price target unchanged to $456 for it. On August 06, 2025, upgrade upgraded it’s rating to Overweight but maintained its price target of $460 on the stock. Wolfe Research downgraded its rating to a Peer Perform. Leerink Partners downgraded its rating to a Market Perform but $503 remained the price target by the analyst firm on May 06, 2025. In a note dated February 12, 2025, Canaccord Genuity upgraded an Hold rating on this stock and boosted its target price from $408 to $424.
For the past year, the stock price of Vertex Pharmaceuticals, Inc fluctuated between $362.50 and $519.88. Currently, Wall Street analysts expect the stock to reach $479.8 within the next 12 months. Vertex Pharmaceuticals, Inc [NASDAQ: VRTX] shares were valued at $410.28 at the most recent close of the market. An investor can expect a potential return of 16.94% based on the average VRTX price forecast.
Analyzing the VRTX fundamentals
According to Vertex Pharmaceuticals, Inc [NASDAQ:VRTX], the company’s sales were 11.39B for trailing twelve months, which represents an 13.33% jump. Gross Profit Margin for this corporation currently stands at 0.86% with Operating Profit Margin at 0.34%, Pretax Profit Margin comes in at 0.38%, and Net Profit Margin reading is 0.32%. To continue investigating profitability, this company’s Return on Assets is posted at 0.15, Equity is 0.22 and Total Capital is 0.2. An extended analysis of the company’s primary financial structure reveals a debt-to-equity ratio of0.09.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 403.00 points at the first support level, and at 395.71 for the second support level. However, for the 1st resistance point, the stock is sitting at 415.43, and for the 2nd resistance point, it is at 420.57.
Ratios To Look Out For
It is important to note that Vertex Pharmaceuticals, Inc [NASDAQ:VRTX] has a current ratio of 2.52. On the other hand, the Quick Ratio is 2.16, and the Cash Ratio is 1.2. Considering the valuation of this stock, the price to sales ratio is 9.23, the price to book ratio is 6.12 and price to earnings (TTM) ratio is 29.33.
Transactions by insiders
Recent insider trading involved Biller Jonathan, EVP and Chief Legal Officer, that happened on Oct 02 ’25 when 694.0 shares were sold. Officer, Biller Jonathan completed a deal on Oct 02 ’25 to buy 694.0 shares. Meanwhile, Director Bhatia Sangeeta N. sold 266.0 shares on Aug 27 ’25.
